Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends

Baldomero, Helen; Aljurf, Mahmoud; Zaidi, Syed Ziauddin A.; Hashmi, Shahrukh K.; Ghavamzadeh, Ardeshir; Elhaddad, Alaa; Hamladji, Rose‐Marie; Ahmed, Parvez; Torjemane, Lamia; Abboud, Miguel R.; Tbakhi, Abdelghani; Khabori, Murtadha Al; Quessar, Asmae; Bazuaye, Nosa; Bekadja, Mohamed Amine; Adil, Salman Naseem; Fahmy, Omar; Ramzi, Mani; Ibrahim, Ahmed; Al-Seraihy, Amal; Abdejalil, Nour Ben; Sarhan, Mahmoud; Huneini, Mohammed Al; Mahmal, Lahoucine; El-Solh, Hassan; Hussain, Fazal; Nassar, A. M.; Alhashmi, Hani; Hamidieh, Amir Ali; Pasquini, Marcelo C.; Kodera, Yoshihisa; Kröger, Nicolaus; Mohty, Mohamad; Jaimovich, Gregorio; Rolón, Juliana Martínez; Paulson, Kristjan; Greinix, Hildegard; Weisdorf, Daniel J.; Horowitz, Mary M.; Núñez, José R.; Gratwohl, Aloïs; Passweg, J.; Koh, Mickey; Szer, Jeff; Niederwieser, Dietger; Novitzky, Nicolás; East-Mediterranean,; Blood, African; Groups, Marrow Transplantation; Transplantation, Marrow

doi:10.1038/s41409-018-0275-5

Cited by 38 publications

(23 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, there was a greater proportion of allotransplants for Hodgkin than non-Hodgkin lymphomas. These data are like those reported by the Eastern Mediterranean Bone Marrow Transplant Group (EMBMT) but different than those reported by the Center for Blood and Marrow Research (CIBMTR) [10]. There was a greater proportion of allotransplants for haemoglobinopathies probably because of the increased incidence in the Middle East including Jordan.…”

contrasting

confidence: 60%

See 1 more Smart Citation

Hematopoietic cell transplants in Jordan: different indications from the US and EU

Halahleh

Sarhan

Gale

et al. 2019

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

contrasting

confidence: 60%

“…If we include the 100 transplants for immune deficiency reported telephonically the proportion of such transplants is 13%, much higher than in the US and EU (6%). Most recipients were referred from neighbouring Arab countries [10]. There were also differences in autotransplant indications with twice as many for Hodgkin versus non-Hodgkin lymphomas.…”

mentioning

confidence: 99%

Hematopoietic cell transplants in Jordan: different indications from the US and EU

Halahleh

Sarhan

Gale

et al. 2019

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

“…Global surveys show a 90% increase overall in HSCT in the World Health Organization (WHO)'s African and Eastern Mediterranean regions from 2006 to 2013, with a 69% and 129% increase in allogeneic and autologous transplants, respectively. [15] The CD34 cell surface marker is primarily used to identify, isolate and enumerate HSPCs. [16] Isolated CD34 + HSPCs are a heterogeneous population, which includes both primitive haematopoietic stem cells (HSCs) and early-and late-stage progenitors (Fig.…”

Section: Researchmentioning

confidence: 99%

Heterogeneity of cell therapy products

et al. 2019

View full text Add to dashboard Cite

Cell therapy entails the administration of living cells that have been purified, propagated or differentiated to create a cell product for a specific therapeutic need. [1] The cell therapy industry initially involved only blood transfusion, haematopoietic stem cell transplantation (HSCT) and reproductive in vitro fertilisation, [2] but has now vastly expanded and will soon be one of the therapeutic pillars of healthcare in the 21st century. [2] Cellular therapies have also diversified over the years and many clinical trials are currently underway (https:// clinicaltrials.gov) to assess the safety and efficacy of various cell types for therapeutic use. One of the major cell types being investigated for therapeutic use is stem cells. Stem cells can be defined as a population of undifferentiated cells capable of asymmetric replication in which, with each cell division, one of the cells retains its self-renewal capability while the other enters a differentiation pathway and becomes a mature cell. [3-5] Stem cells can broadly be divided into three categories based on their differentiation potential, namely totipotent, pluripotent and multipotent (Fig. 1). Totipotent stem cells refer to cells with the ability to produce all cell types of the human body, including the placenta. Examples include zygotes and early blastomeres. [6] Pluripotent stem cells, which include embryonic stem cells and induced pluripotent stem cells, have the ability to differentiate into cells of the three embryonic germ layers (ectoderm, endoderm and mesoderm). [6,7] In contrast, multipotent (also called adult or somatic) stem cells are able to differentiate into a limited number of cell types, usually associated with the tissue in which they reside. [3,6] Adult stem cells have been identified in various tissues of the human body. Examples include neural stromal/stem cells, endometrial stromal/stem cells, mesenchymal stromal/stem cells (MSCs) and haematopoietic stem and progenitor cells (HSPCs). [4,8] MSCs have been isolated from bone marrow, the umbilical cord, adipose tissue and dental pulp. [9,10] The main sources of HSPCs are bone marrow, umbilical cord blood (UCB) and mobilised peripheral blood. HSPCs and MSCs are two of the most extensively studied adult stem cells in research and clinical settings. In this review we discuss the heterogeneous nature of HSPCs and MSCs as well as some of the problems associated with the expansion of these cells for use in therapeutic products in various clinical applications. Heterogeneity Adult stem cells exist in a tightly regulated microenvironment (referred to as a niche) and are dispersed between differentiated cells in various tissues in the body. [11] As a result, the isolated cells are a heterogeneous population, consisting of various subpopulations, including a subpopulation of true stem cells. To date, there is no single phenotypic marker that can unambiguously identify a true stem cell. Thus, currently used therapeutic stem cell products are heterogeneous in nature. Another aspect of heterogeneity ...

show abstract

“…Fundamental elements necessary for establishing a transplantation program were developed during these workshops; however, it became evident that these elements were highly dependent on the prevalence of diseases in different regions and on available resources [6][7][8][9]. These factors drive the types of transplantations needed locally and determine what is affordable or economically feasible [10].…”

Section: Introductionmentioning

confidence: 99%

Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond

Pasquini

Srivastava

Ahmed

et al. 2019

Biology of Blood and Marrow Transplantation

Self Cite

View full text Add to dashboard Cite

Hematopoietic cell transplantation (HCT) is a highly complex procedure that requires a dedicated multidisciplinary team to optimize safety. In addition, institutions may have different needs regarding indications based on regional disease prevalence or may have an interest in developing specialized services. Structured recommendations are not commonly available, however. The Transplant Center and Recipient Issues Standing Committee of the Worldwide Network for Blood and Marrow Transplantation (WBMT) organized a structured review of all pertinent elements for establishing a transplantation program. First, we solicited components from committee members and grouped them into domains (infrastructure, staff, cell processing laboratory, blood banking, laboratory, radiology, pharmacy, HLA testing, ancillary services, and quality). Subsequently, reviewers scored each element on a 7-point scale, ranging from an absolute requirement (score of 1) to not required (score of 7). An independent group of 5 experienced transplantation physicians reviewed the rankings. The minimum requirements for establishing any HCT program were identified among elements with mean score of 2.0, and specific elements for allogeneic and autologous HCT were identified. Mean scores of >2.0 to 4.0 were classified as preferred recommendation, and mean scores of >4.0 to 7.0 were considered ideal recommendations for advanced and complex types of transplantation. This structured set of recommendations guides the prioritization of minimum requirements to establish a transplantation program and set the stage for expansion and further development.

show abstract

Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends

Cited by 38 publications

References 13 publications

Hematopoietic cell transplants in Jordan: different indications from the US and EU

Hematopoietic cell transplants in Jordan: different indications from the US and EU

Heterogeneity of cell therapy products

Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond

Contact Info

Product

Resources

About